RHOBTB3 and acute myeloid leukemia: To explore whether the allo-HSCT treatment could overcome the poorer prognosis caused by down-regulation of RhoBTB3 expression, patients with non-M3 AML in the TCGA database were delivered into two groups (high RhoBTB3, n =79, low RhoBTB3, n =78) according to the median values of RhoBTB3 expression.